Lotus Eye Hospital And Institute Ltd (LOTUSEYE) AI Stock Analysis

• Market Cap: ₹2.22B
• Dividend Yield: N/A
• Average Volume (3M): 2.25K
• Price to Earnings (P/E): 329.0
• Beta (1Y): 0.94
• Revenue Growth: 3.28%
• EPS Growth: -52.11%
• Country: IN
• Employees: 336
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.06
• Shares Outstanding: 20,796,330
• 10 Day Avg. Volume: 678
• 30 Day Avg. Volume: 2,245
• PEG Ratio: -2.60
• Price to Book (P/B): 2.43
• Price to Sales (P/S): 2.94
• P/FCF Ratio: -68.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ₹112.00 ▼(-5.17% Downside)

The overall stock score reflects strong financial fundamentals but is significantly impacted by technical indicators suggesting bearish momentum and a high P/E ratio indicating overvaluation. The lack of dividend yield further detracts from its valuation appeal.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for services and successful market expansion, supporting long-term business sustainability.

Balance Sheet Health

A strong balance sheet with low leverage enhances financial stability and provides flexibility for future growth investments.

Cash Flow Stability

Positive operating cash flow ensures the company can cover its operational expenses and invest in growth opportunities, supporting long-term viability.

Negative Factors

Declining Profit Margins

Shrinking profit margins suggest rising costs or pricing pressures, which could hinder profitability and financial performance over time.

Negative Free Cash Flow

Negative free cash flow indicates potential liquidity issues, limiting the company's ability to invest in growth without external financing.

Profitability Challenges

Declining net profit margins highlight difficulties in converting revenue growth into profit, potentially impacting long-term financial health.

Lotus Eye Hospital And Institute Ltd Business Overview & Revenue Model

Company Description

Lotus Eye Hospital And Institute Ltd (LOTUSEYE) is a premier healthcare institution based in India, specializing in comprehensive eye care services. The hospital operates in the ophthalmology sector, offering a wide range of services including cataract surgery, refractive surgery, glaucoma treatment, and pediatric ophthalmology. With a focus on advanced technology and patient-centric care, LOTUSEYE is dedicated to enhancing the quality of vision and eye health for its patients through specialized treatments and thorough eye examinations.

How the Company Makes Money

LOTUSEYE generates revenue primarily through its medical services and surgeries, which include consultations, diagnostic tests, and various surgical procedures related to eye care. The hospital charges fees for outpatient consultations, inpatient treatments, and surgical interventions, which form the bulk of its income. Additionally, LOTUSEYE may earn revenue from the sale of ophthalmic products, such as eyeglasses, contact lenses, and medications. The company may also benefit from partnerships with insurance providers, which can lead to increased patient volume through covered services. Further revenue can come from specialized eye care programs or community outreach initiatives that promote eye health awareness and preventative care.

Lotus Eye Hospital And Institute Ltd Financial Statement Overview

Summary

Lotus Eye Hospital And Institute Ltd shows strong revenue growth and a solid financial foundation. However, decreasing profit margins and negative free cash flow highlight the need for improved cost management and strategic capital allocation. The balance sheet's low leverage provides a cushion against financial risks.

Income Statement

Lotus Eye Hospital And Institute Ltd has shown steady revenue growth, moving from ₹316.67M in 2021 to ₹495.62M in 2025. The Gross Profit Margin has decreased over the years, from 50.56% in 2021 to 20.26% in 2025, indicating increased cost pressures. The Net Profit Margin has also declined, reflecting challenges in maintaining profitability despite revenue growth.

Balance Sheet

The company maintains a strong equity base with Stockholders' Equity at ₹600.00M in 2025. The Debt-to-Equity ratio is low, suggesting prudent leverage management. However, the Equity Ratio has slightly decreased, indicating a marginal increase in liabilities over time. Overall, the balance sheet remains robust, providing a stable financial foundation.

Cash Flow

Operating Cash Flow has seen fluctuations but remained positive, providing a reliable cash flow source. However, Free Cash Flow has turned negative in recent years, driven by increased capital expenditures, indicating potential liquidity concerns if not balanced with future revenue growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	501.89M	495.63M	482.10M	470.44M	389.10M	323.59M
Gross Profit	223.00M	100.41M	135.66M	121.38M	192.53M	85.70M
EBITDA	44.41M	47.44M	79.42M	88.37M	68.09M	44.59M
Net Income	6.61M	7.39M	29.14M	40.77M	29.84M	15.68M
Balance Sheet
Total Assets	0.00	695.74M	666.27M	631.88M	615.97M	592.29M
Cash, Cash Equivalents and Short-Term Investments	41.51M	39.78M	69.30M	83.31M	87.93M	98.92M
Total Debt	0.00	34.30M	11.10M	11.04M	12.38M	3.99M
Total Liabilities	-600.00M	95.73M	72.17M	56.09M	69.88M	65.32M
Stockholders Equity	600.00M	600.00M	594.09M	575.79M	546.09M	526.97M
Cash Flow
Free Cash Flow	0.00	-21.25M	403.00K	12.90M	-2.73M	22.55M
Operating Cash Flow	0.00	27.02M	56.83M	43.87M	44.12M	27.30M
Investing Cash Flow	0.00	-43.50M	-46.33M	-21.94M	-39.35M	4.86M
Financing Cash Flow	0.00	-12.42M	-34.02M	-17.05M	-15.75M	-3.19M

Lotus Eye Hospital And Institute Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 118.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LOTUSEYE, the sentiment is Neutral. The current price of 118.1 is above the 20-day moving average (MA) of 112.59, above the 50-day MA of 117.38, and above the 200-day MA of 86.37, indicating a neutral trend. The MACD of -3.56 indicates Positive momentum. The RSI at 41.55 is Neutral, neither overbought nor oversold. The STOCH value of 51.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LOTUSEYE.

Lotus Eye Hospital And Institute Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	68 Neutral	₹105.28B	70.08	―	0.20%	16.71%	13.92%
HCG	67 Neutral	₹107.77B	287.35	―	―	17.58%	-38.20%
KRSNAA	62 Neutral	₹24.96B	30.99	―	0.34%	11.51%	21.56%
LOTUSEYE	52 Neutral	₹2.22B	329.01	―	―	3.28%	-52.11%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SHALBY	49 Neutral	₹26.27B	-5,142.71	―	0.58%	11.49%	-91.65%